Senate Panel Urges Balanced Drug Pricing to Protect Public Interest

The Senate Standing Committee on National Health Services urged the government to ensure balanced drug pricing. It called for protecting public interest while maintaining investor confidence and fair profit margins. The committee stressed that essential medicines must stay affordable for everyone.

Focus on Fair Pricing and Reforms

Senator Amir Waliuddin Chishti chaired the meeting at Parliament House. The panel discussed the Drug Regulatory Authority of Pakistan (Amendment) Bill, 2025, and other key issues in the health sector. It recommended a pricing structure that benefits both businesses and the public.
The committee reviewed reports from the Ministry of National Health Services on medicine pricing, hardship cases, and new drug registrations. Members asked the ministry to justify wage increases and production costs. In addition, they urged a review of the Standing Committee on Research (SCR) and ongoing projects to improve transparency and efficiency.
Senator Dr. Zarqa Suharwardy Taimur praised the committee’s efforts and supported its recommendations. However, the health minister warned that sudden regulatory changes could harm the pharmaceutical sector. Therefore, he called for a balanced and stable reform plan. The ministry promised to consult all stakeholders and present a detailed plan of action soon.

Polio Eradication and Public Health Challenges

The committee also reviewed progress on polio eradication. Senator Masroor Ahsan expressed concern over the virus’ persistence despite repeated vaccination drives. The minister said poor sanitation, contaminated water, and unhygienic conditions remain major causes.
Senator Chishti added that vaccination alone cannot succeed without tackling these environmental challenges. He emphasized collective responsibility and accountability from local representatives.